Zomedica enters license and supply agreement with Cresilon Inc.

Phanphen/stock.adobe.com

Zomedica Corp. (Zomedica), a veterinary health company that offers point-of-care diagnostics and therapeutic products for companion and equine animals, shared today that it was entered into a license and supply agreement with Creslion, Inc. This entered agreement gives Zomedica to market and sell Vetigel hemostatic gel producer line on an exclusive basis within the United States and non-exclusive basis outside of the US.

"This partnership with Zomedica is ideal for the future of Vetigel," said Joe Landolina, CEO of Cresilon, in the organizational release.¹ "Zomedica's established reputation, robust field sales team, and commitment to veterinary excellence make them the perfect match for expanding the reach of this revolutionary product. Together, we look forward to making Vetigel an essential tool for veterinary practices worldwide."

According to the release, Vetigel, which made its debut to the market in 2021,² is a plant-based formula that is designed to stop bleeding rapidly when applied directly to the source. The product is made of 2 plant-based polysaccharides that can stop the bleeding immediately at the wound site without manual pressure, preparation, or special storage conditions.³ Vetigel also does not integrate with the robust fibrin patch, creating a mechanical barrier instantly.²

The product stops the bleeding in seconds without becoming incorporated into the clot and was validated in clinical studies. The studies found Vetigel’s ability to save time during surgical procedures and significantly reduce blood loss. Some of the key applications include:

• Dental applications: Successfully managed bleeding in advanced and routine procedures.
• Emergency care: Providing efficacy in treating arterial and venous bleeds.
• Liver biopsy: Demonstrated to stop bleeding faster than competitive hemostatic agents.
• Surgical procedures: Effective in controlling bleeding throughout soft organ biopsies and excisions.

"We are excited to add Vetigel to Zomedica's portfolio of innovative veterinary products," said Kevin Klass, Senior Vice President of Sales at Zomedica. "Vetigel's ability to rapidly stop bleeding across a variety of procedures makes it an invaluable tool for veterinarians, enabling them to enhance patient outcomes while improving surgical efficiency. This partnership with Cresilon allows us to bring cutting-edge solutions to veterinary professionals in the US and beyond."

In 2023, Vetigel was used to help save the life of Benji, a Malteese Yorkie, who was brought into the Veterinary Emergency & Referral Group in Brooklyn, New York with a stab wound.⁴ Matthew Morgan, DVM, DACVS-SA, chief of surgery at VERG, accredited Benji surviving the ordeal to Vetigel.

“Benji came to us in rough shape with a large stab wound,” said Morgan.⁵ “Fortunately, we were able to use Vetigel to stop the traumatic bleeding and ultimately save Benji’s life.”

To learn more information about the Vetigel hemostatic gel, visit the Zomedica website.

References

1. Zomedica Announces License & Supply Agreement with Cresilon Inc. to Market and Sell Vetigel(R) Hemostatic Gel in the Animal Health Market. News release. Zomedica Corp. January 7, 2025. Accessed January 8, 2025.
2. Yankowicz S. VETIGEL comes to the veterinary market. dvm360. August 28, 2023. Accessed January 8, 2025. https://www.dvm360.com/view/vetigel-comes-to-the-veterinary-market
3. Cresilon announces distribution agreement for VETIGEL with Penn Veterinary Supply. News release. Cresilon, Inc. August 22, 2023. Accessed August 28, 2023. https://vetigel.com/blogs/news/cresilon-announces-distribution-agreement-for-vetigel-with-penn-veterinary-supply
4. Dvm360 staff. VERG veterinarians save stabbed Morkie. dvm360. March 1, 2023. Accessed January 8, 2025. https://www.dvm360.com/view/verg-veterinarians-save-stabbed-morkie
5. Emergency veterinarian hospital saves escaped Morkie stabbed in streets of New York. News release. The Veterinary Emergency & Referral Group. March 1, 2023. Accessed January 8, 2025.